Outlook Therapeutics (OTLK) EPS (Basic): 2015-2020
Historic EPS (Basic) for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to $0.02.
- Outlook Therapeutics' EPS (Basic) rose 108.33% to $0.02 in Q3 2020 from the same period last year, while for Sep 2020 it was -$0.99, marking a year-over-year increase of 59.09%. This contributed to the annual value of -$4.06 for FY2024, which is 13.98% up from last year.
- According to the latest figures from Q3 2020, Outlook Therapeutics' EPS (Basic) is $0.02, which was up 166.67% from -$0.03 recorded in Q2 2020.
- Outlook Therapeutics' EPS (Basic)'s 5-year high stood at $0.22 during Q3 2018, with a 5-year trough of -$2.66 in Q1 2018.
- For the 3-year period, Outlook Therapeutics' EPS (Basic) averaged around -$0.72, with its median value being -$0.36 (2020).
- Over the last 5 years, Outlook Therapeutics' EPS (Basic) had its largest YoY gain of 173.33% in 2018, and its largest YoY loss of 854.55% in 2018.
- Quarterly analysis of 5 years shows Outlook Therapeutics' EPS (Basic) stood at -$0.82 in 2016, then grew by 13.41% to -$0.71 in 2017, then slumped by 40.85% to -$1 in 2018, then spiked by 38.00% to -$0.62 in 2019, then surged by 108.33% to $0.02 in 2020.
- Its EPS (Basic) was $0.02 in Q3 2020, compared to -$0.03 in Q2 2020 and -$0.36 in Q1 2020.